Supernus Pharmaceuticals (SUPN) Non-Current Assets (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Non-Current Assets data on file, last reported at $769.1 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 16.59% year-over-year to $769.1 million in Q1 2026; TTM through Mar 2026 was $3.0 billion, a 10.03% increase from a year earlier, with the FY2025 full-year figure at $808.5 million, up 18.54% from the prior year.
• Non-Current Assets for Q1 2026 stood at $769.1 million, down from $808.5 million in the prior quarter.
• Over the last five years, Non-Current Assets for SUPN reached as high as $1.1 billion in Q1 2022 and fell as low as $643.5 million in Q2 2025.
• Historically, Non-Current Assets has averaged $830.2 million across 5 years, with a median of $808.5 million in 2025.
• Across the five-year window, Non-Current Assets fell 18.98% in 2023 and gained 18.54% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $968.4 million in 2022, then slipped by 18.98% to $784.6 million in 2023, then slipped by 13.07% to $682.0 million in 2024, then grew by 18.54% to $808.5 million in 2025, then fell by 4.86% to $769.1 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $769.1 million in Q1 2026, $808.5 million in Q4 2025, and $825.9 million in Q3 2025.